TCGA-AR-A252-01A-11R-A169-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 95
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.560
- INTERFERON_GAMMA_RESPONSE+0.530
- KRAS_SIGNALING_UP+0.470
- INTERFERON_ALPHA_RESPONSE+0.440
- INFLAMMATORY_RESPONSE+0.410
- IL6_JAK_STAT3_SIGNALING+0.390
- COMPLEMENT+0.370
- PROTEIN_SECRETION+0.360
- UV_RESPONSE_DN+0.340
- IL2_STAT5_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- DNA_REPAIR-0.300
- MYC_TARGETS_V1-0.280
- NOTCH_SIGNALING-0.280
- OXIDATIVE_PHOSPHORYLATION-0.260
- E2F_TARGETS-0.250
- GLYCOLYSIS-0.240
- MYOGENESIS-0.210
- UV_RESPONSE_UP-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.861 |
| 2 | 3e17c945-a810-4d82-af11-93debdee3f21 | — | — | 0.848 |
| 3 | TCGA-OR-A5JV-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.834 |
| 4 | TCGA-91-6828-01A-11R-1858-07 | — | cohortA3 | 0.830 |
| 5 | TCGA-97-7553-01A-21R-2039-07 | — | cohortA1 | 0.829 |
| 6 | 7ca9c52f-2d6e-4868-b4e8-9dd7937f6b2b | — | — | 0.824 |
| 7 | 311f1988-e21e-4130-b944-2a34d7d46d28 | — | — | 0.822 |
| 8 | bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b | — | — | 0.820 |
| 9 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.810 |
| 10 | SRR8613773 | — | A | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |